Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
With measles cases at a 35-year high, pediatricians are now considering giving the MMR vaccine as early as 6 months — well before the standard 12-month schedule. A new study adds urgency: most infants lose their maternal measles antibodies by 6 months, leaving a dangerous window of vulnerability. Experts say the decision hinges on geography, travel, and local outbreak risk.
The U.S. is in the grip of its worst measles outbreak since 1991, with more than 5,100 confirmed cases across 46 states and Washington, D.C. — and measles-associated deaths reported in New York, Pennsylvania, and Wisconsin. Falling childhood vaccination rates (now at 92.4% for kindergarteners, below the 95% herd immunity threshold) have fueled the surge, with 96% of cases occurring in unvaccinated individuals.
Amid the crisis, a rarely used CDC recommendation is getting fresh attention: the MMR vaccine can be given to infants as young as 6 months if they live in or are traveling to an area with active measles transmission. Normally, the first dose isn't given until 12–15 months. Experts caution that an early dose doesn't replace the standard two-dose series — it's an added layer of protection for high-risk infants. New research presented at IDWeek adds urgency: a study of 92 mother-infant pairs found that most U.S. infants lose detectable maternal measles antibodies by age 6 months — earlier than previously thought — leaving them vulnerable well before their first scheduled vaccine dose.
By the Numbers:
Why it matters: The U.S. is on the verge of losing its measles-elimination status, achieved in 2000. As outbreaks grow and vaccination rates decline, pediatricians may need to rethink the MMR schedule — potentially moving the first dose earlier for high-risk infants, and accelerating the second dose for those already vaccinated after 12 months.
